Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD22 Positive”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 0 results

Early research (Phase 1)Study completedNCT03919526
What this trial is testing

Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL

Who this might be right for
MRD-positiveAcute Lymphoblastic Leukemia
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 19
Early research (Phase 1)WithdrawnNCT00024115
What this trial is testing

BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
LeukemiaLymphoma
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Looking for participantsNCT06834529
What this trial is testing

CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma

Who this might be right for
Relapsed or Refractory B Cell Leukemia and Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences 20
Early research (Phase 1)Temporarily pausedNCT00077493
What this trial is testing

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
MedImmune LLC 95
Testing effectiveness (Phase 2)Ended earlyNCT03698552
What this trial is testing

ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Who this might be right for
Blasts 5 Percent or More of Bone Marrow Nucleated CellsCD22 PositivePhiladelphia Chromosome Positive+2 more
M.D. Anderson Cancer Center 37
Testing effectiveness (Phase 2)Study completedNCT01363297
What this trial is testing

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

Who this might be right for
Acute Lymphocytic Leukemia
Pfizer 72
Large-scale testing (Phase 3)Ended earlyNCT00562965
What this trial is testing

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Lymphoma, Follicular
Pfizer 29
Early research (Phase 1)UnknownNCT02721407
What this trial is testing

Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients

Who this might be right for
Recurrent Adult Diffuse Large Cell LymphomaRecurrent Follicular LymphomaRecurrent Mantle Cell Lymphoma+3 more
Xinqiao Hospital of Chongqing 20
Early research (Phase 1)Study completedNCT02581878
What this trial is testing

Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma, Non-Hodgkin
Bayer 21
Early research (Phase 1)UnknownNCT04303520
What this trial is testing

Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL

Who this might be right for
CD19-positive ALL
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine 20
Early research (Phase 1)Ended earlyNCT03593109
What this trial is testing

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
Second Affiliated Hospital of Xi'an Jiaotong University 1
Testing effectiveness (Phase 2)Study completedNCT01562990
What this trial is testing

Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse

Who this might be right for
Diffuse Large B-Cell Lymphoma
The Lymphoma Academic Research Organisation 11
Testing effectiveness (Phase 2)Ended earlyNCT03913559
What this trial is testing

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital 5
Post-approval studies (Phase 4)Study completedNCT05687032
What this trial is testing

Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia
Pfizer 44
Early research (Phase 1)UnknownNCT03999697
What this trial is testing

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Who this might be right for
Diffuse Large B Cell LymphomaFollicular LymphomaPrimary Cutaneous Follicle Centre Lymphoma+4 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Testing effectiveness (Phase 2)Study completedNCT02311998
What this trial is testing

Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML

Who this might be right for
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlasts More Than 5 Percent of Bone Marrow Nucleated Cells+4 more
M.D. Anderson Cancer Center 22
Testing effectiveness (Phase 2)Looking for participantsNCT03739814
What this trial is testing

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Who this might be right for
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRecurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI) 84
Early research (Phase 1)Active Not RecruitingNCT03241940
What this trial is testing

Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies

Who this might be right for
B Acute Lymphoblastic LeukemiaCD19 PositiveMinimal Residual Disease+4 more
Stanford University 33